JULIUS O. ENORU

• Global DMPK Scientific Lead and SME for CYP Induction and Transporter Subject Matter Areas: Provided scientific direction and oversight for CYP induction and transporter studies from Lead Generation through Candidate Nomination/Selection to IND. Oversaw study report authoring and signed off on IND reports, as well as provided responses to regulatory agency inquiries, following strict compliance with global regulatory Drug Interaction guidelines (ICH M12/FDA/EMA).
• DMPK Project team representative for Phase 1 Oncology project: provided DMPK scientific strategic direction while collaborating across functions (Clinical pharmacology, Safety toxicology, Project Management, Clinical Operations, Regulatory Affairs etc.), to drive project advancement.
• Leadership: Led and mentored team of scientists, managed capital budgets, evaluated performance, and directed overall strategy to enhance team productivity and effectiveness.
• · Drove strong collaboration with medicinal chemistry, preclinical pharmacology, safety tox counterparts. Provided updates and presentations at cross-functional DMPK/Medicinal Chemistry Led and managed scientific team to drive project success. Team Meetings.
• Represented AbbVie in the IQ working group for Targeted Covalent Inhibitors (TCI)
• Served as TCI SME for AbbVie projects
• Performed annual IB updates and responded to regulatory agency inquiries.
• TCI working group activities resulted in the publication of industry guidance for the development of TCI.

• Translational in vitro ADME group Leader (SME): Served as team lead and DMPK Team Representative for Oncology projects, providing DMPK strategic scientific direction and leading a team of scientists supporting drug Discovery project teams through different milestones.

· Oversaw study designs and IND report writing for – clearance, protein binding, plasma id, plasma stability, CYP induction studies etc. from Lead Generation through Candidate Nomination/Selection to IND.

· Led a team of scientists – provided mentoring and developing team members, while managing capital budgets, evaluated employee performance and drove overall scientific strategy of the team.

• Designed and executed in vitro studies for drug discovery and development projects, collaborating with contract research laboratories. Provided in vitro DMPK support to drug development project teams, ensuring alignment with project goals.
• Designed oncology assays supporting AbbVie research programs.
• Analyzed experimental data using statistical and visualization tools.
• Coordinated cross-functional studies with chemistry, biology, and development teams.

• Advised and guided startups and small biotech clients on regulatory (FDA, EMA, ICH) requirements for various drug development projects, managing client expectations to ensure satisfaction.
• Established In Vitro DMPK laboratory and line of business, developing proposals, protocols and validating assays for laboratory use.
• Provide scientific and leadership oversight of the DMPK group, ensuring studies are performed using high quality standards, and following regulatory guidances and SOPs.
• Directed studies: generated proposals, protocols, and reports for clients' IND enabling studies, ensuring regulatory compliance throughout study conduct.

• Promoted to positions of increasing responsibility from Postdoctoral Fellow to Principal Research Scientist I.
• Principal Research Scientist I: 2009 2010
• Senior Research Scientist II: 2007 2009
• Senior Research Scientist I: 2004 2007
• Postdoctoral Research Fellow: 2002 2004
• DMPK Project Team Representative for Cardiovascular & Metabolic Diseases and Neuroscience programs: Provided in-depth analysis and interpretation of in vitro ADME/PK data for compound progression from LG to CN/CS to IND.
• Provided DMPK strategy, communicated issues to departmental management, and coordinated key DMPK activities under aggressive timelines.
• Presented data at cross-functional meetings and contributed towards preparation of governance committee presentations to facilitate go/no-go decisions for project milestones.
• Delivered value-added DMPK data and reports for IND submissions, leading discussions at monthly strategy review meetings, and contributing to responses for inquiries from regulatory agencies.
• Led custom assays and technology development initiatives
• Reduced turn-around time by 25% and improved inter-departmental communications by working across functions, streamlining study execution, data analysis and reporting procedures.
• Provided advice on drug-drug interactions to clinical teams, by evaluating all development compounds for the ability to induce CYP450 enzymes.
• 2002-2004: Completed Wyeth's DMPK postdoctoral program.
• Developed, validated and implemented a CYP450 induction assay for for use in routine screening in early Discovery stage

• External Scientific Engagement
• 2024 - Present:
• Represent AbbVie at DMPK IQ working group on Targeted Covalent Inhibitors (TCI)
• 2024 - Present: International Society for the Study of Xenobiotics (ISSX)
• ISSX Africa Steering committee Co-chair (2025-2028) and 2025 meeting organizing committee co-chair. Resulted in the launch of ISSX Africa and a 2026 ASAE award.
• Internal Leadership Activities.
• Organized community outreaches to promote AbbVie giveback activities.
• 2023 - 2026: Co-chaired AbbVie Bay Area Black Business Network (BBN) employee resource group (ERG), partnering with other ERGs to foster cultural initiatives at South San Francisco site and across AbbVie.
• 2023 - 2026: Contributed as a member of the AbbVie Community of Science (CoS) planning committee; participated in selecting committee member in the CoS poster and satellite session winners for 3 years.